vs

Side-by-side financial comparison of BALCHEM CORP (BCPC) and CORCEPT THERAPEUTICS INC (CORT). Click either name above to swap in a different company.

BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $202.1M, roughly 1.3× CORCEPT THERAPEUTICS INC). BALCHEM CORP runs the higher net margin — 14.9% vs 12.0%, a 2.9% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 8.1%). CORCEPT THERAPEUTICS INC produced more free cash flow last quarter ($38.4M vs $33.8M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 7.5%).

Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

BCPC vs CORT — Head-to-Head

Bigger by revenue
BCPC
BCPC
1.3× larger
BCPC
$270.7M
$202.1M
CORT
Growing faster (revenue YoY)
CORT
CORT
+3.1% gap
CORT
11.1%
8.1%
BCPC
Higher net margin
BCPC
BCPC
2.9% more per $
BCPC
14.9%
12.0%
CORT
More free cash flow
CORT
CORT
$4.6M more FCF
CORT
$38.4M
$33.8M
BCPC
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
7.5%
BCPC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BCPC
BCPC
CORT
CORT
Revenue
$270.7M
$202.1M
Net Profit
$40.3M
$24.3M
Gross Margin
98.7%
Operating Margin
20.5%
2.2%
Net Margin
14.9%
12.0%
Revenue YoY
8.1%
11.1%
Net Profit YoY
8.7%
-21.0%
EPS (diluted)
$1.25
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCPC
BCPC
CORT
CORT
Q1 26
$270.7M
Q4 25
$263.6M
$202.1M
Q3 25
$267.6M
$207.6M
Q2 25
$255.5M
$194.4M
Q1 25
$250.5M
$157.2M
Q4 24
$240.0M
$181.9M
Q3 24
$239.9M
$182.5M
Q2 24
$234.1M
$163.8M
Net Profit
BCPC
BCPC
CORT
CORT
Q1 26
$40.3M
Q4 25
$39.2M
$24.3M
Q3 25
$40.3M
$19.7M
Q2 25
$38.3M
$35.1M
Q1 25
$37.1M
$20.5M
Q4 24
$33.6M
$30.7M
Q3 24
$33.8M
$47.2M
Q2 24
$32.1M
$35.5M
Gross Margin
BCPC
BCPC
CORT
CORT
Q1 26
Q4 25
35.6%
98.7%
Q3 25
35.7%
97.8%
Q2 25
36.4%
98.2%
Q1 25
35.2%
98.5%
Q4 24
36.0%
98.4%
Q3 24
35.6%
98.4%
Q2 24
35.5%
98.5%
Operating Margin
BCPC
BCPC
CORT
CORT
Q1 26
20.5%
Q4 25
19.8%
2.2%
Q3 25
20.4%
4.9%
Q2 25
20.1%
13.7%
Q1 25
20.4%
2.2%
Q4 24
19.8%
13.9%
Q3 24
20.0%
25.5%
Q2 24
19.6%
21.7%
Net Margin
BCPC
BCPC
CORT
CORT
Q1 26
14.9%
Q4 25
14.9%
12.0%
Q3 25
15.1%
9.5%
Q2 25
15.0%
18.1%
Q1 25
14.8%
13.1%
Q4 24
14.0%
16.9%
Q3 24
14.1%
25.9%
Q2 24
13.7%
21.7%
EPS (diluted)
BCPC
BCPC
CORT
CORT
Q1 26
$1.25
Q4 25
$1.21
$0.20
Q3 25
$1.24
$0.16
Q2 25
$1.17
$0.29
Q1 25
$1.13
$0.17
Q4 24
$1.03
$0.25
Q3 24
$1.03
$0.41
Q2 24
$0.98
$0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCPC
BCPC
CORT
CORT
Cash + ST InvestmentsLiquidity on hand
$72.9M
$372.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.3B
$647.8M
Total Assets
$1.7B
$836.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCPC
BCPC
CORT
CORT
Q1 26
$72.9M
Q4 25
$74.6M
$372.2M
Q3 25
$65.1M
$421.7M
Q2 25
$65.4M
$342.2M
Q1 25
$49.9M
$322.8M
Q4 24
$49.5M
$383.3M
Q3 24
$73.7M
$380.3M
Q2 24
$63.7M
$473.2M
Stockholders' Equity
BCPC
BCPC
CORT
CORT
Q1 26
$1.3B
Q4 25
$1.3B
$647.8M
Q3 25
$1.3B
$631.9M
Q2 25
$1.3B
$635.8M
Q1 25
$1.2B
$683.3M
Q4 24
$1.1B
$679.6M
Q3 24
$1.2B
$638.8M
Q2 24
$1.1B
$596.2M
Total Assets
BCPC
BCPC
CORT
CORT
Q1 26
$1.7B
Q4 25
$1.7B
$836.7M
Q3 25
$1.7B
$823.6M
Q2 25
$1.7B
$801.7M
Q1 25
$1.6B
$846.5M
Q4 24
$1.6B
$840.6M
Q3 24
$1.6B
$784.3M
Q2 24
$1.6B
$714.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCPC
BCPC
CORT
CORT
Operating Cash FlowLast quarter
$40.1M
$38.4M
Free Cash FlowOCF − Capex
$33.8M
$38.4M
FCF MarginFCF / Revenue
12.5%
19.0%
Capex IntensityCapex / Revenue
2.3%
0.0%
Cash ConversionOCF / Net Profit
0.99×
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCPC
BCPC
CORT
CORT
Q1 26
$40.1M
Q4 25
$67.3M
$38.4M
Q3 25
$65.6M
$54.5M
Q2 25
$47.3M
$43.9M
Q1 25
$36.5M
$5.1M
Q4 24
$52.3M
$59.3M
Q3 24
$51.3M
$73.8M
Q2 24
$45.0M
$41.2M
Free Cash Flow
BCPC
BCPC
CORT
CORT
Q1 26
$33.8M
Q4 25
$38.4M
Q3 25
Q2 25
$43.9M
Q1 25
$5.0M
Q4 24
$59.2M
Q3 24
$72.2M
Q2 24
$40.8M
FCF Margin
BCPC
BCPC
CORT
CORT
Q1 26
12.5%
Q4 25
19.0%
Q3 25
Q2 25
22.6%
Q1 25
3.2%
Q4 24
32.5%
Q3 24
39.5%
Q2 24
24.9%
Capex Intensity
BCPC
BCPC
CORT
CORT
Q1 26
2.3%
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
0.3%
Cash Conversion
BCPC
BCPC
CORT
CORT
Q1 26
0.99×
Q4 25
1.72×
1.58×
Q3 25
1.63×
2.77×
Q2 25
1.23×
1.25×
Q1 25
0.98×
0.25×
Q4 24
1.56×
1.93×
Q3 24
1.52×
1.56×
Q2 24
1.40×
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons